Compare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AUROBINDO PHARMA ALKEM LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 23.4 17.1 136.7% View Chart
P/BV x 5.6 3.7 152.4% View Chart
Dividend Yield % 0.9 0.3 302.4%  

Financials

 ALKEM LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
AUROBINDO PHARMA
Mar-19
ALKEM LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,720830 327.7%   
Low Rs1,660527 315.0%   
Sales per share (Unadj.) Rs697.9333.9 209.0%  
Earnings per share (Unadj.) Rs96.140.4 238.2%  
Cash flow per share (Unadj.) Rs117.351.8 226.6%  
Dividends per share (Unadj.) Rs25.002.50 1,000.0%  
Dividend yield (eoy) %1.10.4 309.8%  
Book value per share (Unadj.) Rs515.2237.1 217.3%  
Shares outstanding (eoy) m119.57585.91 20.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.0 154.4%   
Avg P/E ratio x22.816.8 135.5%  
P/CF ratio (eoy) x18.713.1 142.5%  
Price / Book Value ratio x4.32.9 148.5%  
Dividend payout %26.06.2 419.8%   
Avg Mkt Cap Rs m261,879397,569 65.9%   
No. of employees `00014.317.9 80.3%   
Total wages/salary Rs m15,05525,849 58.2%   
Avg. sales/employee Rs Th5,822.610,956.9 53.1%   
Avg. wages/employee Rs Th1,050.51,447.7 72.6%   
Avg. net profit/employee Rs Th802.01,324.3 60.6%   
INCOME DATA
Net Sales Rs m83,444195,636 42.7%  
Other income Rs m1,0421,553 67.1%   
Total revenues Rs m84,486197,189 42.8%   
Gross profit Rs m14,73439,519 37.3%  
Depreciation Rs m2,5286,680 37.8%   
Interest Rs m6512,626 24.8%   
Profit before tax Rs m12,59831,767 39.7%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,1057,269 15.2%   
Profit after tax Rs m11,49323,645 48.6%  
Gross profit margin %17.720.2 87.4%  
Effective tax rate %8.822.9 38.3%   
Net profit margin %13.812.1 114.0%  
BALANCE SHEET DATA
Current assets Rs m54,960153,645 35.8%   
Current liabilities Rs m32,433120,429 26.9%   
Net working cap to sales %27.017.0 159.0%  
Current ratio x1.71.3 132.8%  
Inventory Days Days80135 58.9%  
Debtors Days Days7264 113.3%  
Net fixed assets Rs m32,710103,909 31.5%   
Share capital Rs m239586 40.8%   
"Free" reserves Rs m61,368138,322 44.4%   
Net worth Rs m61,607138,908 44.4%   
Long term debt Rs m1,5921,800 88.5%   
Total assets Rs m99,433264,544 37.6%  
Interest coverage x20.413.1 155.5%   
Debt to equity ratio x00 199.5%  
Sales to assets ratio x0.80.7 113.5%   
Return on assets %12.29.9 123.0%  
Return on equity %18.717.0 109.6%  
Return on capital %21.023.8 87.9%  
Exports to sales %19.149.6 38.4%   
Imports to sales %3.018.8 15.8%   
Exports (fob) Rs m15,91797,091 16.4%   
Imports (cif) Rs m2,48336,741 6.8%   
Fx inflow Rs m16,06197,316 16.5%   
Fx outflow Rs m2,48340,589 6.1%   
Net fx Rs m13,57856,727 23.9%   
CASH FLOW
From Operations Rs m5,85116,220 36.1%  
From Investments Rs m-7,414-28,768 25.8%  
From Financial Activity Rs m79219,191 4.1%  
Net Cashflow Rs m-7316,656 -11.0%  

Share Holding

Indian Promoters % 66.9 54.1 123.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.0 416.4%  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.2 -  
Shareholders   68,381 69,601 98.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NEULAND LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 450 Points Higher; BPCL Jumps 4%(09:30 am)

Asian share markets are trading on a mixed note today as stocks extended the global rally as a halt in a recent bond markets sell-off eased investor nerves and lifted riskier assets.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 2, 2021 10:34 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS